This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2024 Zacks Investment Research | 10 S Riverside Plaza Suite #1600 | Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +24.20% per year. These returns cover a period from January 1, 1988 through April 1, 2024. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Zacks News
AbbVie (ABBV) to Buy Landos to Strengthen Autoimmune Portfolio
by Zacks Equity Research
AbbVie (ABBV) offers to buy Landos Biopharma (LABP) to boost its portfolio in inflammatory and autoimmune disease drugs.
AbbVie (ABBV) Announces Appointment of New CEO Robert Michael
by Zacks Equity Research
Robert Michael is set to succeed Richard A. Gonzalez as AbbVie's (ABBV) CEO, effective Jul 1, 2024.
Karuna (KRTX) Up 48% on $14B Buyout Offer From Bristol Myers
by Zacks Equity Research
Bristol Myers (BMY) is set to acquire Karuna (KRTX) for $330 per share. This transaction is expected to close in the first half of 2024.
Cerevel Therapeutics Holdings, Inc. (CERE)'s Technical Outlook is Bright After Key Golden Cross
by Zacks Equity Research
Should investors be excited or worried when a stock's 50 -day simple moving average crosses above the 200-day simple moving average?
AbbVie (ABBV) to Acquire Cerevel Therapeutics (CERE) for $8.7B
by Zacks Equity Research
AbbVie (ABBV) offers to buy Cerevel Therapeutics (CERE) for $8.7 billion. The acquisition will strengthen AbbVie's neuroscience pipeline.
Wall Street Analysts Think Cerevel Therapeutics Holdings, Inc. (CERE) Could Surge 27.31%: Read This Before Placing a Bet
by Zacks Equity Research
The mean of analysts' price targets for Cerevel Therapeutics Holdings, Inc. (CERE) points to a 27.3% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement among analysts in raising earnings estimates does indicate an upside in the stock.
Why Cerevel Therapeutics (CERE) Might Surprise This Earnings Season
by Zacks Equity Research
Cerevel Therapeutics (CERE) is seeing favorable earnings estimate revision activity and has a positive Zacks Earnings ESP heading into earnings season.
Zacks.com featured highlights include: Hibbett, Integer Holdings, Cerevel Therapeutics Holdings and A10 Networks
by Zacks Equity Research
Zacks.com featured highlights include: Hibbett, Integer Holdings, Cerevel Therapeutics Holdings and A10 Networks
New Analyst Coverage Puts Spotlight on These 4 Stocks
by Shrabana Mukherjee
Increased analyst coverage over the past few weeks might lead to solid price appreciation for stocks like HIBB, ITGR, CERE and ATEN.
Cerevel (CERE) Novel Schizophrenia Drug Succeeds in Phase I
by Zacks Equity Research
Cerevel Therapeutics (CERE) surges as schizophrenia candidate, CVL-231, demonstrates clinically meaningful and statistically significant improvement in PANSS Total score at 6 weeks in phase Ia study.
Company News for Jun 30, 2021
by Zacks Equity Research
Companies in the news are: EPAC, CERE, PLBY, MRNA